Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQ01 609C→T mutation and rapid fractional excretion of chlorzoxazone

Cancer Research

Volumn 57, Issue 14, 1997, Pages 2839-2842

  Rothman, Nathaniel ^a   Smith, Martyn T ^b   Hayes, Richard B ^a   Traver, Robert D ^c   Hoener, Betty Ann ^d   Campleman, Sharan ^b   Li, Gui Lan ^e   Dosemeci, Mustafa ^a   Linet, Martha ^a   Zhang, Luoping ^b   Xi, Liqiang ^e   Wacholder, Sholom ^a   Lu, Wei ^f   Meyer, Kathleen B ^b   Titenko Holland, Nina ^b   Stewart, James T ^g   Yin, Songnian ^e   Ross, David ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^f Shanghai Hygiene and Anti Epidemic Center   (China)

^g UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENE; CARCINOGEN; CHLORZOXAZONE;

ACUTE NONLYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER RISK; CHINA; COHORT ANALYSIS; CONTROLLED STUDY; GENE MUTATION; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; OCCUPATIONAL CANCER; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

BENZENE; CHLORZOXAZONE; COHORT STUDIES; CYTOCHROME P-450 CYP2E1; HEMATOLOGIC NEOPLASMS; HUMANS; MUTATION; NAD(P)H DEHYDROGENASE (QUINONE); OCCUPATIONAL EXPOSURE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0030849791     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. IARC. Monographs on the Evaluation of Carcinogenic Risks to Man. IARC Scientific Publ. No. 29, pp. 93-148. Lyon, France: IARC, 1982.
2. Hayes, R. B., Yin, S-N., Dosemeci, M., Li, G-L., Wacholder, S., Travis, L. B., Li, C-Y., Rothman, N., Hoover, R. N., Linet, M.S., and the Benzene Study Group, Benzene and the dose-related incidence of lymphohematopoietic malignancies in China. J. Natl. Cancer Inst., in press, 1997.
3. Aksoy, M. Benzene hematotoxicity. In: M. Aksoy (ed.), Benzene Carcinogenicity, pp. 59-104. Boca Raton, FL: CRC Press Inc., 1988.
4. Kalf, G. F. Recent advances in the metabolism and toxicity of benzene. Crit. Rev. Toxicol., 18: 141-159, 1987.
5. Koop, D. R., Laethem, C. L., and Schnier, G. G. Identification of ethanol-inducible P450 isozyme 3a(P450IIE1) as a benzene and phenol hydroxylase. Toxicol. Appl. Pharmacol., 98: 278-288, 1989.
6. Eastmond, D. A., Smith, M. T., and Irons, R. D. An interaction of benzene metabolites reproduces the myelotoxicity observed with benzene exposure. Toxicol. Appl. Pharmacol., 91: 85-95, 1987.
7. Smith, M. T., Yager, J. W., Steinmetz, K. L., and Eastmond, D. A. Peroxidase-dependent metabolism of benzene's phenolic metabolites and its potential role in benzene toxicity and carcinogenicity. Environ. Health Perspect., 82: 23-29, 1989.
8. Ross, D. Metabolic basis of benzene toxicity. Eur. J. Hematol., 60 (Suppl): 111-118, 1996.
9. De Vries, J. D., Salphati, L., Horie, S., Becker, C. E., and Hoener, B-A. Variability in the disposition of chlorzoxazone. Biopharm. & Drug Dispos., 15: 587-597, 1994.
10. Travis, L. B., Li, C. Y., Zhang, Z. N., Li, D. G., Yin, S. N., Chow, W. H., Li, G. L., Dosemeci, M., Blot, W., Fraumeni, J. F., Jr., Hayes, R. B., and Linet, M. S. Hematopoietie malignancies and related disorders among benzene-exposed workers in China. Leuk. & Lymphoma. 14: 91-102, 1994.
11. Dosemeci, M., Li, G-L., Hayes, R. B., Yin, S-N., Linet, M., Chow, W-H., Wang, Y-Z., Jiang, Z-L., Dai, T-R., Zhang, W-U., Chao, X-J., Ye, P-Z., Kou, Q-R., Fan, Y-H., Zhang, X-C., Lin, X-F., Meng, J-F., Zho, J-S., Wacholder, S., Kneller, R., and Blot, W. J. A cohort study among workers exposed to benzene in China. II. Exposure assessment. Am. J. Ind. Med., 26: 401-411, 1994.
12. Chinese Ministry of Public Health, Diagnostic criteria and principles of management of occupational benzene poisoning: 1982. In: S. Yin and G. Li (eds.), Toxicological and Epidemiological Studies of Benzene in China, pp. 198-199. Beijing, China: Inslitute of Occupational Medicine, Chinese Academy of Preventive Medicine, 1994.
13. Park, D. J., and Koeffler, H. P. Therapy-related acute myelocytic leukemia. In: P. H. Wiernik, G. P. Canellow, J. P. Dutcher, and R. A. Kyle (eds.). Neoplastic Diseases of the Blood, pp. 381-407. New York: Churchill-Livingstone, Inc., 1996.
14. Peter, R., Bocker, R., Beaune, P. H., Iwasaki, M., Guengerich, F. P., and Yang, C. S. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol., 3: 566-573, 1990.
15. Gelboin, H. V., Goldfarb, I., Krausz, K. W., Grogan, J., Korzekwa, K. R., Gonzalez, F. J., and Shou, M. Inhibitory and noninhibitory monoclonal antibodies to human cytochrome P450 2E1. Chem. Res. Toxicol., 9: 1023-1030, 1996.
16. Zhang, H., and Stewart, J. T. Improved high performance liquid chromatographic determination of chlorzoxazone and its hydroxy metabolite in human serum and urine. Anal. Lett., 26: 675-687, 1993.
17. Hayashi, S-I., Watanabe, J., and Kawajiri, K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J. Biochem. (Tokyo), 110: 559-565, 1991.
18. Watanabe, J., Hayashi, S-I., Nakachi, K., Imai, K., Suda, Y., Sekine, T., and Kawajiri, K. PstI and RsaI in complete linkage disequilibrium at the CYP2E gene. Nucleic Acids Res., 18: 7194, 1990.
19. Traver, R. D., Horikoshi, T., Danenberg, K. D., Stadlbauer, T. H. W., Danenberg, P. V., Ross, D., and Gibson, N. W. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res., 52: 797-802, 1992.
20. Traver, R. D., Siegel, D., Beall, H. D., Phillips, R. M., Gibson, N. W., Franklin, W. A., and Ross, D. Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). Br. J. Cancer. 75: 69-75, 1997.
21. Rosvold, E. A., McGlynn, K. A., Lustbader, E. D., and Buetow, K. H. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics, 5: 199-206, 1995.
22. Eickelmann, P., Schulz, W. A., Rohde, D., Schmitz-Drager, B., and Sies, H. Loss of heterozygosity at the NAD(P)H:quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol. Chem. Hoppe-Scyler, 375: 439-445, 1994.
23. Rothman, N., Li, G-L., Doscmeci, M., Bechtold, W. E., Marti, G. E., Wang, Y-Z., Linet, M., Xi, L-J., Lu, W., Smith, M. T., Titenko-Holland, N., Zhang, L-P., Blot, W., Yin, S-N., and Hayes, R. B. Hematotoxicity among Chinese workers heavily exposed to benzene. Am. J. Ind. Med., 29: 236-246, 1996.
24. Aksoy, M., and Erdem, S. Follow-up study on the mortality and the development of leukemia in 44 pancytopenic patients with chronic exposure to benzene. Blood, 52: 285-292, 1978.
25. Yin, S-N., Li, G-L., Tain, F-D., Fu, Z-I., Jin, C., Chen, Y-J., Luo, S-J., Ye, P-Z., Zhang, J-Z., Wang, G-C., Zhang, X-C., Wu, H-N., and Zhong, Q-C. Leukemia in benzene workers: a retrospective cohort study. Br. J. Ind. Med., 44: 124-128, 1987.
26. Kim, S. G., Shehin, S. E., States, J. C. and Novak, R. F. Evidence for increased translational efficiency in the induction of P450IIE1 by solvents: analysis of P450IIE1 mRNA polyribosomal distribution. Biochem. Biophys. Res. Commun., 172: 767-774, 1990.
27. Watanabe, J., Hayashi, S-I, and Kawajiri, K. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′-flanking region. J. Biochem., 116: 321-326, 1994.
28. Vesell, E. S., Seaton, T. D., and A-Rahim, Y. I. Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. Pharmacogenetics, 5: 53-57, 1995.
29. Dreisbach, A. W., Ferencz, N., Hopkins, N. E., Fuentes, M. G., Rege, A. B., George, W. J., and Lertora, J. J. L. Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity. Clin. Pharmacol. & Ther., 58: 498-505, 1995.
30. Kim, R. B., O'Shea, D., and Wilkinson, G. R. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin. Pharmacol. & Ther., 57: 645-655, 1995.
31. Carriere, V., Goasduff, T., Ratanasavanh, D., Morel, F., Gautier, J-C., Guillouzo, A., Beaune, P., and Berthou, F. Both cytochrome P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem. Res. Toxicol., 6: 852-857, 1993.
32. Ono, S., Hatanaka, T., Hotta, H., Tsutsui, M., Satoh, T., and Gonzalez, F. J. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics, 5: 143-150, 1995.
33. Beyer, R. E., Segura-Aguilar, J., Di Bernardo, S., Cavazzoni, M., Fato, R., Fiorentini, D., Galli, M. C., Setti, M., Landi, L., and Lenaz, G. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc. Natl. Acad. Sci USA, 93: 2528-2532, 1996.
34. Siegel, D., Bolton, E. M., Burr, J. A., Liebler, D. C., and Ross, D. The reduction of α-tocopherolquinone by human NAD(P)H:quinone oxidoreductase (hNQO1): the role of α-tocopherolhydroquinone as a cellular antioxidant. Proc. Am. Assoc. Cancer Res., 38: 132, 1997.
35. Larson, R. A., Banerjee, M., Wang, Y., Wiemels, J., Hartford, C., Le Beau, M. M., and Smith, M. T. An inactivating polymorphism in the NAD(PH):quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia (t-AML). Proc. Am. Soc. Clinical Oncol. Annu. Meet., 1997.